What is HC Wainwright’s Forecast for PRQR FY2028 Earnings?

ProQR Therapeutics N.V. (NASDAQ:PRQR) – Equities researchers at HC Wainwright lowered their FY2028 earnings per share (EPS) estimates for ProQR Therapeutics in a research report issued on Thursday, October 1st. HC Wainwright analyst A. Ghosh now expects that the biopharmaceutical company will post earnings per share of ($0.37) for the year, down from their prior forecast of ($0.27). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for ProQR Therapeutics’ current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for ProQR Therapeutics’ FY2029 earnings at ($0.32) EPS and FY2030 earnings at ($0.18) EPS.

ProQR Therapeutics (NASDAQ:PRQR) last posted its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.04. The firm had revenue of $10.00 million for the quarter, compared to analyst estimates of $4.56 million. ProQR Therapeutics had a negative return on equity of 73.83% and a negative net margin of 223.51%.

Several other research firms have also issued reports on PRQR. Chardan Capital reaffirmed a “buy” rating and set a $3.00 price target on shares of ProQR Therapeutics in a research report on Thursday, October 1st. Citigroup reissued a “market outperform” rating on shares of ProQR Therapeutics in a research report on Thursday, October 1st. Wall Street Zen upgraded shares of ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 15th. JonesTrading dropped their target price on shares of ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, June 26th. Finally, Bank of America began coverage on shares of ProQR Therapeutics in a research note on Thursday, August 20th. They issued a “buy” rating and a $8.00 target price for the company. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, ProQR Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.60.

ProQR Therapeutics Trading Down 1.2%

NASDAQ:PRQR opened at $1.65 on Monday. ProQR Therapeutics has a 1-year low of $1.33 and a 1-year high of $3.10. The firm has a fifty day simple moving average of $1.93 and a 200 day simple moving average of $1.76. The stock has a market capitalization of $173.84 million, a PE ratio of -3.59 and a beta of 0.20.

Insider Buying and Selling at ProQR Therapeutics

In related news, Director Bart Filius acquired 150,000 shares of ProQR Therapeutics stock in a transaction on Friday, July 17th. The stock was purchased at an average cost of $1.72 per share, with a total value of $258,000.00. Following the completion of the transaction, the director directly owned 300,000 shares in the company, valued at $516,000. This trade represents a 100.00% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Daniel de Boer acquired 150,000 shares of ProQR Therapeutics stock in a transaction on Thursday, July 9th. The shares were bought at an average cost of $1.74 per share, with a total value of $261,000.00. Following the completion of the transaction, the chief executive officer owned 300,000 shares of the company’s stock, valued at approximately $522,000. This trade represents a 100.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 8.40% of the company’s stock.

Institutional Trading of ProQR Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Walleye Capital LLC raised its holdings in ProQR Therapeutics by 2.7% in the 1st quarter. Walleye Capital LLC now owns 607,529 shares of the biopharmaceutical company’s stock valued at $984,000 after acquiring an additional 15,744 shares during the period. Bank of America Corp DE boosted its holdings in shares of ProQR Therapeutics by 6.4% during the first quarter. Bank of America Corp DE now owns 185,110 shares of the biopharmaceutical company’s stock worth $300,000 after acquiring an additional 11,186 shares during the period. RFG Advisory LLC boosted its holdings in shares of ProQR Therapeutics by 236.8% during the second quarter. RFG Advisory LLC now owns 64,000 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 45,000 shares during the period. Finally, Axiom Investment Management LLC acquired a new position in shares of ProQR Therapeutics in the first quarter valued at approximately $53,000. Institutional investors own 32.65% of the company’s stock.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a biotechnology company focused on developing RNA-based medicines for genetic diseases. The company’s research is centered on using RNA therapies to correct or modify disease-causing genetic information, with the goal of addressing conditions that may not be effectively treated through conventional drug-development approaches.

ProQR’s technology portfolio includes Axiomer, an RNA-editing platform designed to make precise changes to RNA inside cells. The company has also developed investigational therapies for inherited retinal diseases and other genetic disorders.